SCHEMBL20147607

SCHEMBL20147607

CC(C)N1CCC(C)(NC(=O)c2ccccn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 3/20 0.45
GAA P10253 2/20 0.45
FPR2 P25090 1/20 0.45
GRM5 P41594 1/20 0.45
CCR1 P32246 1/20 0.45
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
OPRD1 P41143 1/20 0.43
KCNH2 Q12809 1/20 0.43
ANO1 Q5XXA6 1/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 2/20 0.42
PRKCB P05771 1/20 0.42
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069803 0.85 KDM4E (0.48) KDM4EALDH1A1HTTKMT2AGAA
SCHEMBL29836003 0.85 GRM5 (0.53) KDM4EALDH1A1HTTKMT2AGAA
SCHEMBL20147641 0.84 P2RX7 (0.38) RET
SCHEMBL20147653 0.84 P2RX7 (0.44) KMT2AANO1RET
SCHEMBL20147654 0.82 RET (0.42) GRM5CCR1ANO1RET
SCHEMBL30043736 0.82 GRM5 (0.57) KDM4EALDH1A1HTTKMT2AGAA
SCHEMBL21652051 0.82 RAD52 (0.46) KDM4EHTTKMT2AGAAFPR2
SCHEMBL20626718 0.82 KDM4E (0.45) KDM4EALDH1A1HTTKMT2AGAA
SCHEMBL20147617 0.82 PABPC1 (0.47) KDM4EALDH1A1HTTRAB9ANPC1
SCHEMBL20147610 0.81 RET (0.51) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 KDM4E 547/4885ALDH1A1 2547/4885HTT 3338/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KDM4E 547/4885ALDH1A1 2547/4885HTT 3338/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 KDM4E 547/4885ALDH1A1 2547/4885HTT 3338/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KDM4E 547/4885ALDH1A1 2547/4885HTT 3338/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KDM4E 547/4885ALDH1A1 2547/4885HTT 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.